How Substance P and Other Neuropeptides Drive Inflammation Through Two Waves of Cell Signaling | Research

The takeaway

Neuropeptides like substance P trigger inflammation through two separate signaling waves — one at the cell surface and one from inside the cell — and targeting the internal wave could be a more selective anti-inflammatory approach.

2 signaling waves
Neuropeptides trigger inflammation both at the cell surface and from inside endosomes, each controlled by different enzymes

What the researchers found

Neuropeptides like substance P drive inflammation through two distinct signaling waves: one at the cell surface and a second from inside the cell after the receptor is internalized into endosomes. Enzymes at each location control the intensity of these signals.

Deleting neprilysin (a surface enzyme that breaks down substance P) worsens inflammation because more pro-inflammatory peptide accumulates. Conversely, blocking ECE-1 (an enzyme inside endosomes) actually reduces inflammation by preventing receptors from recycling back to the surface for another round of signaling. β-arrestin proteins, which shuttle receptors into endosomes, also play a direct role in inflammatory cell migration and pro-inflammatory signaling.

Why it matters

Most anti-inflammatory drugs target receptors at the cell surface with a broad, blunt approach. This review reveals that neuropeptide-driven inflammation has two distinct phases — surface signaling and endosomal signaling — that can be targeted independently. Blocking the endosomal recycling pathway (via ECE-1 inhibition) could offer a more selective anti-inflammatory strategy that dampens sustained inflammation without shutting down all receptor activity.

The numbers in context

Not applicable (narrative review)

How the study worked

Narrative review synthesizing research on GPCR signaling mechanisms for neuropeptides, integrating findings from cell-based studies and genetic knockout models to map how plasma membrane and endosomal signaling contribute to inflammation.

Who was studied

Not applicable (review of cell-based and animal model research)

What this study cannot tell us

Most of the mechanisms described were studied in model cell systems rather than in vivo human disease. The relative contribution of plasma membrane versus endosomal signaling in complex inflammatory diseases remains unclear. No clinical data on targeting these pathways therapeutically.

How to read the evidence

This is a narrative review synthesizing cell biology and knockout animal studies. It provides a strong mechanistic framework but relies primarily on model systems rather than clinical data. Rated moderate because the mechanistic evidence is compelling but clinical translation remains unproven.

When this study was published

Published in 2013. The endosomal signaling concepts described here have since become well-established in GPCR pharmacology and have influenced drug development strategies for pain and inflammation.

The bigger picture

This work connects neuropeptide biology to a growing understanding that cell signaling doesn't stop when a receptor leaves the surface. The concept of 'endosomal signaling' has since reshaped drug development across many fields, including pain and inflammation research. For peptide science specifically, it shows that the enzymes controlling peptide degradation — both outside and inside cells — are potential drug targets that could lead to more precise anti-inflammatory therapies.

Questions still open

Could ECE-1 inhibitors become a new class of anti-inflammatory drugs that work by blocking neuropeptide receptor recycling?
How do these dual signaling pathways operate in human inflammatory diseases like arthritis or inflammatory bowel disease?
Do other neuropeptides besides substance P use the same two-wave signaling mechanism to drive chronic inflammation?

Common questions

What is endosomal signaling and why does it matter for inflammation?

After a neuropeptide like substance P binds its receptor on the cell surface, the receptor gets pulled inside the cell into small compartments called endosomes. From there, it continues to send inflammatory signals — a 'second wave.' This matters because blocking only the surface signal leaves the endosomal signal running, which may be why some anti-inflammatory drugs don't fully control inflammation.

Could this research lead to better treatments for chronic inflammatory diseases?

Potentially. The review suggests that targeting the enzymes controlling receptor recycling (like ECE-1) could dampen sustained inflammation more selectively than current drugs. This approach would allow normal short-term inflammatory responses while blocking the prolonged signaling that drives chronic disease.

Read the original research

Arresting inflammation: contributions of plasma membrane and endosomal signalling to neuropeptide-driven inflammatory disease.

Biochemical Society transactions, 41(1), 137-43

View on PubMed ↗Publisher’s paper ↗

Citation

Cattaruzza, Fiore; Poole, Daniel P; Bunnett, Nigel W. (2013). Arresting inflammation: contributions of plasma membrane and endosomal signalling to neuropeptide-driven inflammatory disease.. Biochemical Society transactions, 41(1), 137-43. https://doi.org/10.1042/BST20120343